|Awarded On||November 19, 2014|
|Title||Pre-IND Development of OxaliTex|
|Award Mechanism||Bridging the Gap: Early Translational Research Awards|
|Institution/Organization||The University of Texas at Austin|
|Principal Investigator/Program Director||Jonathan Sessler|
Platinum chemotherapy is the go-to therapy for many cancers including NSCLC and ovarian cancer. Unfortunately, cisplatin and the two other FDA-approved platinum drugs oxaliplatin and carboplatin are highly non-selective, meaning they attack healthy tissue in addition to the tumor. This dose-limiting problem is compounded when the patient has developed platinum resistant cancer. Platinum resistance is considered responsible in large measure for the low (5-20%) 5-year survival rates seen in these cancers.
The PI’s research group at The Univ. of Texas at Austin (UTA) has specialized in developing cancer-specific anticancer agents (called texaphyrins) for the last 20 years. An recent collaborati...